AnPac Announces Two New Insurance Customers In China For Its Cancer Screening And Detection Tests

AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio" or the "Company") (NASDAQ:ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and

Benzinga · 02/06/2020 13:25

AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio" or the "Company") (NASDAQ:ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, today announced that it has gained two new insurance customers in China for its cancer screening and detection tests ("CDA tests") using its cancer differentiation analysis, or CDA, technology.

The two insurance customers are Bohai Life Insurance Co., Ltd. ("Bohai Life") and PKU Founder Life Insurance Co., Ltd., Qingdao Branch ("Founder Life Qingdao" hereafter). Under its service agreements with these insurance companies, the Company provides their insurance clients with several multi-cancer, standardized CDA tests to assess the individuals' cancer risks. Business with insurance companies has played an important role in AnPac Bio's growth.